Co-Diagnostics, Inc. Announces New Additions to Board of Directors
27 June 2019 - 8:30PM
Business Wire
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of molecular diagnostic tests, announced today that Dr.
Eugene Durenard and Mr. Ted Murphy have joined the Board of
Directors of Co-Diagnostics, and will serve on the Board’s
Compensation and Corporate Governance/Nominating Committees and
Audit Committees as independent directors.
Dr. Durenard brings a thorough multi-asset class investment and
entrepreneurial experience spanning 20 years to the Board of
Directors. He is the founder and CEO of Hyperbolic Holdings, a
Swiss-based holding, management consulting and investment advisory
company specialized in healthcare since February 2018; co-founder
and CIO of Healthcare Impact Holdings, an investment fund
specialized in later-stage healthcare private ventures since May
2018; co-founder and trustee of Healthcare Impact Foundation, a
charitable organization designed to sustainably fund translation of
innovation in life sciences since September 2017; co-founder of
Global Better Health, a platform designed to provide
scientifically-based corporate wellness and preventive programs
since December 2018; and an advisor to and Managing Director of the
Stetson Family Office since September 2016. Dr. Durenard received
his PhD in Mathematics at Harvard in 1995 before beginning his
career with Salomon Brothers in London.
Mr. Murphy has been senior partner in a private investment firm
from June 1999 to the present. His duties have included investment
analysis of various types of investment projects in health care,
real estate and financial services. Mr. Murphy serves on the board
of directors of three Canadian publicly reporting companies that
have interests in various industries.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company’s technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release include statements regarding the (i) use of funding
proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in liquid biopsy and SNP detection,
(iv) use of the Company’s liquid biopsy tests by laboratories, (v)
capital resources and runway needed to advance the Company’s
products and markets, (vi) increased sales in the near-term, (vii)
flexibility in managing the Company’s balance sheet, (viii)
anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from those
contemplated or anticipated by such forward-looking statements.
Readers of this press release are cautioned not to place undue
reliance on any forward-looking statements. The Company does not
undertake any obligation to update any forward-looking statement
relating to matters discussed in this press release, except as may
be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190627005271/en/
Andrew Benson Co-Diagnostics Investor Relations 801-438-1036
investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2024 to May 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From May 2023 to May 2024